2019 was a good year for Medistim, with continued growth and profitability. We have further strengthened our position within cardiac bypass surgery, particularly in our most important market USA.
We have now achieved a market penetration of 23% in USA, measured as the share of bypass procedures done with Medistim’s devices. Our position in Asia and Europe is also strengthened, through increased sales and installed base.
During 2019, the multi center registry study – REQUEST – received a lot of positive attention. Some of the best cardiac centers in Europe, Canada and the United States participated in the study. The results from the REQUEST study showed that 25% of the patient population had one or more surgical changes made to the procedure based on data obtained from high frequency ultrasound (HFUS) and TTFM. This is a high figure, indicating that using HFUS imaging together with TTFM has great clinical benefit during the CABG procedure, even for highly experienced surgeons.
We believe the REQUEST study will continue to be an important piece of clinical evidence and support future growth for Medistim.
Read the full report below (only available in English):